Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2012

Open Access 01-12-2012 | Research article

Role of emmprin in endometrial cancer

Authors: Keiichiro Nakamura, Junichi Kodama, Atsushi Hongo, Yuji Hiramatsu

Published in: BMC Cancer | Issue 1/2012

Login to get access

Abstract

Background

Extracellular matrix metalloproteinase inducer (Emmprin/CD147) is a transmembrane glycoprotein that belongs to the immunoglobulin superfamily. Enriched on the surface of many tumor cells, emmprin promotes tumor growth, invasion, metastasis and angiogenesis. We evaluated the clinical importance of emmprin and investigated its role in endometrial cancer.

Methods

Emmprin expression was examined in uterine normal endometrium, endometrial hyperplasia and cancer specimens by immunohistochemistry. In addition, the biological functions and inhibitory effects of an emmprin knockdown were investigated in HEC-50B and KLE endometrial cancer cell lines.

Results

The levels of emmprin expression were significantly increased in the endometrial cancer specimens compared with the normal endometrium and endometrial hyperplasia specimens (p < 0.05). The disease-free survival (DFS) and overall survival (OS) rates of patients with high emmprin expression were significantly higher than those of patients with low emmprin expression (DFS: p < 0.001; OS: p < 0.001). Emmprin knockdown by the siRNA led to cell proliferation, migration and invasion through TGF-β, EGF, NF-κB, VEGF, MMP-2, and MMP-9 expression, which in turn resulted in increased levels of E-cadherin and reduced levels of Vimentin and Snail in endometrial cancer.

Conclusions

The present findings suggest that low emmprin expression might be a predictor of favorable prognosis in endometrial cancer patients, and that emmprin may represent a potential therapeutic target for endometrial cancer.
Appendix
Available only for authorised users
Literature
1.
Jemal A, Siegel R, Xu J, Ward E: Cancer statistics, 2010. CA Cancer J Clin. 2010, 60: 277-300. 10.3322/caac.20073.CrossRefPubMed
2.
Annual Report of Oncology Committee of Japan Society of Obstetrics and Gynecology. Acta Obstet et gynaecol Japon. 2012, 64: 1043-1054. Japanese.
3.
Biswas C, Zhang Y, DeCastro R, Guo H, Nakamura T, Kataoka H, Nabeshima K: The human tumor cell-derived collagenase stimulatory factor (renamed EMMPRIN) is a member of the immunoglobulin superfamily. Cancer Res. 1995, 55: 434-439.PubMed
4.
Guo H, Majmudar G, Jensen TC, Biswas C, Toole BP, Gordon MK: Characterization of the gene for human EMMPRIN, a tumor cell surface inducer of matrix metalloproteinases. Gene. 1998, 220: 99-108. 10.1016/S0378-1119(98)00400-4.CrossRefPubMed
5.
Muramatsu T, Miyauchi T: Basigin (CD147): a multifunctional transmembrane protein involved in reproduction, neural function, inflammation and tumor invasion. Histol Histopathol. 2003, 18: 981-987.PubMed
6.
Chen X, Kanekura T, Kanzaki T: Expression of Basigin in human fetal, infantile and adult skin and in basal cell carcinoma. J Cutan Pathol. 2001, 28: 184-190. 10.1034/j.1600-0560.2001.028004184.x.CrossRefPubMed
7.
Gabison EE, Hoang-Xuan T, Mauviel A, Menashi S: EMMPRIN/CD147, an MMP modulator in cancer, development and tissue repair. Biochimie. 2005, 87: 361-368. 10.1016/j.biochi.2004.09.023.CrossRefPubMed
8.
Zhu P, Ding J, Zhou J, Dong WJ, Fan CM, Chen ZN: Expression of CD147 on monocytes/macrophages in rheumatoid arthritis: its potential role in monocyte accumulation and matrix metalloproteinase production. Arthritis Res Ther. 2005, 7: 1023-1033. 10.1186/ar1778.CrossRef
9.
Nabeshima K, Iwasaki H, Koga K, Hojo H, Suzumiya J, Kikuchi M: Emmprin (basigin/CD147): matrix metalloproteinase modulator and multifunctional cell recognition molecule that plays a critical role in cancer progression. Pathol Int. 2006, 56: 359-367. 10.1111/j.1440-1827.2006.01972.x.CrossRefPubMed
10.
Yan L, Zucker S, Toole BP: Roles of the multifunctional glycoprotein, emmprin (basigin; CD147), in tumour progression. Thromb Haemost. 2005, 93: 199-204.PubMed
11.
Jin JS, Yao CW, Loh SH, Cheng MF, Hsieh DS, Bai CY: Increasing expression of extracellular matrix metalloprotease inducer in ovary tumors: tissue microarray analysis of immunostaining score with clinicopathological parameters. Int J Gynecol Pathol. 2006, 25: 140-146. 10.1097/01.pgp.0000189244.57145.84.CrossRefPubMed
12.
Sameshima T, Nabeshima K, Toole BP, Yokogami K, Okada Y, Goya T, Koono M, Wakisaka S: Expression of emmprin (CD147), a cell surface inducer of matrix metalloproteinases, in normal human brain and gliomas. Int J Cancer. 2000, 88: 21-27. 10.1002/1097-0215(20001001)88:1<21::AID-IJC4>3.0.CO;2-S.CrossRefPubMed
13.
Zheng HC, Takahashi H, Murai Y, Cui ZG, Nomoto K, Miwa S, Tsuneyama K, Takano Y: Upregulated EMMPRIN/CD147 might contribute to growth and angiogenesis of gastric carcinoma: a good marker for local invasion and prognosis. Br J Cancer. 2006, 95: 1371-1378. 10.1038/sj.bjc.6603425.CrossRefPubMedPubMedCentral
14.
Bordador LC, Li X, Toole B, Chen B, Regezi J, Zardi L, Hu Y, Ramos DM: Expression of emmprin by oral squamous cell carcinoma. Int J Cancer. 2000, 85: 347-352. 10.1002/(SICI)1097-0215(20000201)85:3<347::AID-IJC9>3.0.CO;2-#.CrossRefPubMed
15.
Kanekura T, Chen X, Kanzaki T: Basigin (CD147) is expressed on melanoma cells and induces tumor cell invasion by stimulating production of matrix metalloproteinases by fibroblasts. Int J Cancer. 2002, 99: 520-528. 10.1002/ijc.10390.CrossRefPubMed
16.
Li Y, Xu J, Chen L, Zhong WD, Zhang Z, Mi L, Zhang Y, Liao CG, Bian HJ, Jiang JL, Yang XM, Li XY, Fan CM, Zhu P, Fu L, Chen ZN: HAb18G (CD147), a cancer-associated biomarker and its role in cancer detection. Histopathology. 2009, 54: 677-687. 10.1111/j.1365-2559.2009.03280.x.CrossRefPubMed
17.
Zhang Q, Zhou J, Ku XM, Chen XG, Zhang L, Xu J, Chen GS, Li Q, Qian F, Tian R, Wen N, Chen ZN: Expression of CD147 as a significantly unfavorable prognostic factor in hepatocellular carcinoma. Eur J Cancer Prev. 2007, 16: 196-202. 10.1097/01.cej.0000236245.40619.c3.CrossRefPubMed
18.
Tan H, Ye K, Wang Z, Tang H: CD147 expression as a significant prognostic factor in differentiated thyroid carcinoma. Transl Res. 2008, 152: 143-149. 10.1016/j.trsl.2008.07.005.CrossRefPubMed
19.
Reimers N, Zafrakas K, Assmann V, Egen C, Riethdorf L, Riethdorf S, Berger J, Ebel S, Jänicke F, Sauter G, Pantel K: Expression of extracellular matrix metalloproteases inducer on micrometastatic and primary mammary carcinoma cells. Clin Cancer Res. 2004, 10: 3422-3428. 10.1158/1078-0432.CCR-03-0610.CrossRefPubMed
20.
Hagemann T, Wilson J, Kulbe H, Li NF, Leinster DA, Charles K, Klemm F, Pukrop T, Binder C, Balkwill FR: Macrophages induce invasiveness of epithelial cancer cells via NF-kappa B and JNK. J Immunol. 2005, 175: 1197-1205.CrossRefPubMed
21.
Tang Y, Nakada MT, Kesavan P, McCabe F, Millar H, Rafferty P, Bugelski P, Yan L: Extracellular matrix metalloproteinase inducer stimulates tumor angiogenesis by elevating vascular endothelial cell growth factor and matrix metalloproteinases. Cancer Res. 2005, 65: 3193-3199.PubMed
22.
Yang J, Weinberg RA: Epithelial-mesenchymal transition: at the crossroads of development and tumor metastasis. Dev Cell. 2008, 14: 818-829. 10.1016/j.devcel.2008.05.009.CrossRefPubMed
23.
Christiansen JJ, Rajasekaran AK: Reassessing epithelial to mesenchymal transition as a prerequisite for carcinoma invasion and metastasis. Cancer Res. 2006, 66: 8319-8326. 10.1158/0008-5472.CAN-06-0410.CrossRefPubMed
24.
Berx G, Raspé E, Christofori G, Thiery JP, Sleeman JP: Pre-EMTing metastasis? Recapitulation of morphogenetic processes in cancer. Clin Exp Metastasis. 2007, 24: 587-597. 10.1007/s10585-007-9114-6.CrossRefPubMed
25.
Moustakas A, Heldin CH: Signaling networks guiding epithelial -mesenchymal transitions during embryogenesis and cancer progression. Cancer Sci. 2007, 98: 1512-1520. 10.1111/j.1349-7006.2007.00550.x.CrossRefPubMed
26.
Batlle E, Sancho E, Francí C, Domínguez D, Monfar M, Baulida J, García De Herreros A: The transcription factor snail is a repressor of E-cadherin gene expression in epithelial tumour cells. Nat Cell Biol. 2000, 2: 84-89. 10.1038/35000034.CrossRefPubMed
27.
Cano A, Pérez-Moreno MA, Rodrigo I, Locascio A, Blanco MJ, del Barrio MG, Portillo F, Nieto MA: The transcription factor snail controls epithelial -mesenchymal transitions by repressing E-cadherin expression. Nat Cell Biol. 2000, 2: 76-83. 10.1038/35000025.CrossRefPubMed
28.
Hajra KM, Chen DY, Fearon ER: The SLUG zinc-finger protein represses E-cadherin in breast cancer. Cancer Res. 2002, 62: 1613-1618.PubMed
29.
Yang J, Mani SA, Donaher JL, Ramaswamy S, Itzykson RA, Come C, Savagner P, Gitelman I, Richardson A, Weinberg RA: Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell. 2004, 117: 927-939. 10.1016/j.cell.2004.06.006.CrossRefPubMed
30.
Li M, Zhai Q, Bharadwaj U, Wang H, Li F, Fisher WE, Chen C, Yao Q: Cyclophilin A is overexpressed in human pancreatic cancer cells and stimulates cell proliferation through CD147. Cancer. 2006, 106: 2284-2294. 10.1002/cncr.21862.CrossRefPubMed
31.
Soulitzis N, Karyotis I, Delakas D, Spandidos DA: Expression analysis of peptide growth factors VEGF, FGF2, TGFB1, EGF and IGF1 in prostate cancer and benign prostatic hyperplasia. Int J Oncol. 2006, 29: 305-314.PubMed
32.
Cheng H, Fukushima T, Takahashi N, Tanaka H, Kataoka H: Hepatocyte growth factor activator inhibitor type 1 regulates epithelial to mesenchymal transition through membrane-bound serine proteinases. Cancer Res. 2009, 69: 1828-1835. 10.1158/0008-5472.CAN-08-3728.CrossRefPubMed
33.
Ueda K, Yamada K, Urashima M, Ishibashi Y, Shirai M, Nikaido T, Takahashi H, Okamoto A, Saito M, Yasuda M, Ohkawa K, Tanaka T: Association of extracellular matrix metalloproteinase inducer in endometrial carcinoma with patient outcomes and clinicopathogenesis using monoclonal antibody 12C3. Oncol Rep. 2007, 17: 731-735.PubMed
34.
Rucci N, Millimaggi D, Mari M, Del Fattore A, Bologna M, Teti A, Angelucci A, Dolo V: Receptor activator of NF-kappaB ligand enhances breast cancer-induced osteolytic lesions through upregulation of extracellular matrix metalloproteinase inducer/CD147. Cancer Res. 2010, 70: 6150-6160. 10.1158/0008-5472.CAN-09-2758.CrossRefPubMed
35.
Zhu H, Zhao J, Zhu B, Collazo J, Gal J, Shi P, Liu L, Ström AL, Lu X, McCann RO, Toborek M, Kyprianou N: EMMPRIN regulates cytoskeleton reorganization and cell adhesion in prostate cancer. Prostate. 2012, 72: 72-81. 10.1002/pros.21408.CrossRefPubMed
36.
Xue YJ, Lu Q, Sun ZX: CD147 overexpression is a prognostic factor and a potential therapeutic target in bladder cancer. Med Oncol. 2011, 28: 1363-1372. 10.1007/s12032-010-9582-4.CrossRefPubMed
37.
Wang B, Xu YF, He BS, Pan YQ, Zhang LR, Zhu C, Qu LL, Wang SK: RNAi-mediated silencing of CD147 inhibits tumor cell proliferation, invasion and increases chemosensitivity to cisplatin in SGC7901 cells in vitro. J Exp Clin Cancer Res. 2010, 29: 61-10.1186/1756-9966-29-61.CrossRefPubMedPubMedCentral
38.
Wang L, Wu G, Yu L, Yuan J, Fang F, Zhai Z, Wang F, Wang H: Inhibition of CD147 expression reduces tumor cell invasion in human prostate cancer cell line via RNA interference. Cancer Biol Ther. 2006, 5: 608-614. 10.4161/cbt.5.6.2661.CrossRefPubMed
39.
Bougatef F, Menashi S, Khayati F, Naïmi B, Porcher R, Podgorniak MP, Millot G, Janin A, Calvo F, Lebbé C, Mourah S: EMMPRIN promotes melanoma cells malignant properties through a HIF-2alpha mediated up-regulation of VEGF-receptor-2. PLoS One. 2010, 5: e12265-10.1371/journal.pone.0012265.CrossRefPubMedPubMedCentral
40.
Wu J, Ru NY, Zhang Y, Li Y, Wei D, Ren Z, Huang XF, Chen ZN, Bian H: HAb18G/CD147 promotes epithelial-mesenchymal transition through TGF-β signaling and is transcriptionally regulated by Slug. Oncogene. 2011, 30: 4410-4427. 10.1038/onc.2011.149.CrossRefPubMed
41.
Venkatesan B, Valente AJ, Prabhu SD, Shanmugam P, Delafontaine P, Chandrasekar B: EMMPRIN activates multiple transcription factors in cardiomyocytes, and induces interleukin-18 expression via Rac1-dependent PI3K/Akt/IKK/NF-kappaB andMKK7/JNK/AP-1 signaling. J Mol Cell Cardiol. 2010, 49: 655-663. 10.1016/j.yjmcc.2010.05.007.CrossRefPubMedPubMedCentral
42.
Min C, Eddy SF, Sherr DH, Sonenshein GE: NF-kappaB and epithelial to mesenchymal transition of cancer. J Cell Biochem. 2008, 104: 733-744. 10.1002/jcb.21695.CrossRefPubMed
Metadata
Title
Role of emmprin in endometrial cancer
Authors
Keiichiro Nakamura
Junichi Kodama
Atsushi Hongo
Yuji Hiramatsu
Publication date
01-12-2012
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2012
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-12-191

Other articles of this Issue 1/2012

BMC Cancer 1/2012 Go to the issue

Research article

Identification of PADI2 as a potential breast cancer biomarker and therapeutic target

Research article

Adeno-associated virus-mediated doxycycline-regulatable TRAIL expression suppresses growth of human breast carcinoma in nude mice

Research article

REGγ is associated with multiple oncogenic pathways in human cancers

Research article

Genetic oxidative stress variants and glioma risk in a Chinese population: a hospital-based case–control study

Research article

Effect of the MDM2 promoter polymorphisms SNP309T>G and SNP285G>C on the risk of ovarian cancer in BRCA1 mutation carriers

Research article

MGMT, GATA6, CD81, DR4, and CASP8 gene promoter methylation in glioblastoma
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits